Dersleri yüzünden oldukça stresli bir ruh haline sikiş hikayeleri bürünüp özel matematik dersinden önce rahatlayabilmek için amatör pornolar kendisini yatak odasına kapatan genç adam telefonundan porno resimleri açtığı porno filmini keyifle seyir ederek yatağını mobil porno okşar ruh dinlendirici olduğunu iddia ettikleri özel sex resim bir masaj salonunda çalışan genç masör hem sağlık hem de huzur sikiş için gelip masaj yaptıracak olan kadını gördüğünde porn nutku tutulur tüm gün boyu seksi lezbiyenleri sikiş dikizleyerek onları en savunmasız anlarında fotoğraflayan azılı erkek lavaboya geçerek fotoğraflara bakıp koca yarağını keyifle okşamaya başlar
Reach Us +1-947-333-4405

GET THE APP

Significance Of HER2 Genetic Heterogeneity Detected By Fluorescence In Situ Hybridization Analysis In Invasive Ductal Breast Carcinoma | 28260
ISSN: 2161-0681

Journal of Clinical & Experimental Pathology
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Significance of HER2 genetic heterogeneity detected by fluorescence in situ hybridization analysis in invasive ductal breast carcinoma

4th International Conference and Exhibition on Pathology

K H Ramesh

ScientificTracks Abstracts-Workshop: J Clin Exp Pathol

DOI: 10.4172/2161-0681.S1.016

Abstract
Breast cancer is the most common malignancy in women of all ethnicities. Standard treatment involves surgical resection; pathologic analyses that includes morphologic, immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) analysis to determine ER, PR and HER2 parameters in the tumor. The HER2 gene (17q11.2-12) is amplified in 20% of invasive breast cancers. Patients with tumor positive-HER2 gene amplification are eligible for adjuvant chemotherapy with Trastuzumab (Herceptin) resulting in longer survival. Studies have shown that 40% of breast tumors show genetic heterogeneity (GH) as per ASCO/CAP (2013) criteria. Breast tumors with an IHC score of 2+ qualify for FISH testing to rule out HER2 gene amplification and if positive, patients are eligible for Herceptin treatment. GH is defined as the presence of >5% and <50% of 20 tumor cells showing HER2-amplification. The 40% of breast tumors that show GH pose an unresolved dilemma in treatment. Our aim is to establish the clinical significance of HER2 GH in breast cancer. Data is correlated with patient demographics, histological tumor type and stage, IHC scores, treatment regimen and morbidity to determine if GH has an impact on treatment modality. These outcomes include differences in survival (Kaplan-Meyer survival curves) and morbidity from the treatment (cardiomyopathy). Our hope is to determine whether a systematic study of outcomes among patients with HER2 GH with or without equivocal FISH results will address reconsiderations of treatment guidelines for these patients.
Biography
K H Ramesh did his PhD in Human Cancer Cytogenetics from Bangalore University, India. He trained under the guidance of world renowned Geneticist Avery Sandberg, MD at Roswell Park Cancer Institute, Buffalo, USA. He is Board Certified in Clinical Cytogenetics; currently a Diplomate of the American Board of Medical Genetics and Genomics and Fellow of the American College of Medical Genetics and Genomics. At present he is the Director of Cancer CytoGenomics and Associate Professor of Pathology at Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, USA. He has over 25 years of experience in Human Cancer Genetics.
Top